NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Obsidian Therapeutics, Inc. (OBX) Stock Analysis

Obsidian Therapeutics, Inc. (OBX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

OBX

$16.82

−$0.27 (−1.58%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OBX with… →

OBX Key Statistics

As of Sep 4, 2026
Trading
Open
$17.26
Previous Close
$17.09
Day's Range
16.57–19.00
52-Week Range
14.57–49.97
Volume
140.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.60
Valuation
Market Cap
$1.04B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.55
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$100.61M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.77M
Dividend and dates
Avg Volume
117.10K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OBX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$100.61M—
2024$0.00−$83.11M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$105.67M−$100.61M—
2024$0.00—−$91.26M−$83.11M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OBX Valuation vs Biotechnology Median

Median of 656 stocks
MetricOBXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Obsidian Therapeutics, Inc. (OBX) is capitalised at $1.04B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 87 employees.

OBX last closed at $16.82 on September 4, 2026. That is −$0.27 (−1.58%) against the previous close. The 52-week range on file runs from $14.57 to $49.97. The latest close sits 15.44% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $100.61M. The reported profit margin is 0%. Trailing earnings per share are −1.55.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 2.6.

Growth & Income

No dividend is on file for OBX.

So far in 2026 the price is −3.89%.

Peer Comparison

Obsidian Therapeutics, Inc. (OBX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Obsidian Therapeutics, Inc. OBX $1.04B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Obsidian Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Visit website →